Geburtshilfe Frauenheilkd 2020; 80(10): e202
DOI: 10.1055/s-0040-1718173
Poster
Mittwoch, 7.10.2020
Gynäkologische Onkologie III

Chemotherapy Response Score: Correlation with preoperative assessment of serological response and clinical implications in ovarian cancer patients

Ramspott JP
1   Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Deutschland
,
MacKintosh ML
2   St Mary’s Hospital, Manchester University Hospitals NHS Trust, Gynaecological Oncology, Manchester, Vereinigtes Königreich
,
Langner AK
3   Frauenarztpraxis Dr. med. Ludger Pass, Köln, Deutschland
,
A Traut
1   Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Deutschland
,
B Ataseven
1   Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Deutschland
4   LMU Klinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
,
M Bommert
1   Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Deutschland
,
F Heitz
1   Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Deutschland
,
S Prader
1   Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Deutschland
,
S Schneider
1   Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Deutschland
,
Waltering KU
5   Kliniken Essen-Mitte, Department of Radiology, Essen, Deutschland
,
S Heikaus
6   Kliniken Essen-Mitte, Department of Pathology, Essen, Deutschland
,
P Harter
1   Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Deutschland
,
A du Bois
1   Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Deutschland
,
T Baert
1   Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Deutschland
7   Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgien
› Author Affiliations
› Further Information
Also available at
 
 

    Aims Evaluation of the clinical value of the chemotherapy response score (CRS) and comparison with serological response to neoadjuvant chemotherapy (NACT) in FIGO III/IV epithelial ovarian cancer patients.

    Methods In a retrospective analysis of 182 patients undergoing interval debulking after NACT response to chemotherapy was evaluated using CRS. CRS values were correlated to preoperative serological (CA125) findings using the GCIG criteria, progression free survival (PFS), and overall survival (OS).

    Results In this cohort 29.1 % (53/182) of patients had a CRS3, 47.8 % (87/182) CRS2 and 23.1 % (42/182) CRS1. Patients with CRS3 showed a longer median PFS (31.2 months, P=0.001) and OS (92.1 months, P=0.004) compared to patients with CRS1/2 (19.7 and 39.9 months). A pathological complete remission (pCR) led to a longer median PFS (53.6 months) compared to non-pCR CRS3 (28.2 months). CRS correlated with serological response to NACT (κ=0.126, P=0.014). Patients with serological complete remission showed longer PFS (26.9 months, P=0.033) and OS (65.8 months, P=0.011) compared to patients with partial remission (PR) (18 and 36.1 months), stable (SD), or progressive disease (PD) (14.1 and 29.5 months). We observed no significant differences between PFS and OS based on response to NACT by CRS or CA125 (CRS1/2 vs. CA125-SD/PR and CRS3 vs. CA125-CR).

    Conclusion In our cohort both serological response and CRS correlated with prognosis. We observed no added value for CRS as a prognostic marker in comparison to evaluation of serological response to NACT. As currently no therapeutic consequences result from CRS the clinical relevance of CRS should be discussed.


    #

    Interessenkonflikt

    Es bestehen keine Interessenkonflikte.

    Publication History

    Article published online:
    07 October 2020

    © 2020. Thieme. All rights reserved.
    Rüdigerstraße 14, 70469 Stuttgart, Germany